drugset / Trial / NCT04921930
Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)
Phase 1/2
Completed
20 enrolled
French National Institute of Health and Medical Research
Imagine Institute · collab
NaSingle-groupOpen-labelTreatment
Summary
This dose-escalation study is aimed at investigating a novel application for artesunate in the treatment of Friedreich ataxia. It will evaluate this novel application of oral artesunate using a surrogate biological marker as primary endpoint in a phase I-II open trial
Timeline
- Start
- 2022-05-06
- Primary completion
- 2024-04-17
- Completion
- 2024-04-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Artesunate | Small molecule | 100 mg | Oral |